Potentials of nivolumab in the treatment of refractory Hodgkin’s lymphoma: literature review and authors’ own observation

DOI: https://dx.doi.org/10.18565/pharmateca.2018.12.33-38

M.Yu. Kichigina (1), E.A. Demina (2), G.S. Tumyan (1), E.A. Osmanov (3), P.A. Zeynalova (1)

1 N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia; 2 Department of Hematology and Cell Therapy, Institute of Advanced Medical Studies, National Medical and Surgical Center N.I. Pirogov, Moscow, Russia; 3 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Immunotherapy with a PD-1 inhibitor (nivolumab) is highly effective in relapses and refractory forms of classical Hodgkin’s lymphoma (HL). In some cases, the use of this drug is considered the only possible treatment option for these patients with extremely unfavorable prognosis. The article describes the clinical observation of a female patient with relapses and a refractory course of HL, who underwent initiation of an early access program on the use of nivoluumab after 10 years of treatment of classical LH with various chemotherapy regimens, radiation therapy, and surgical treatment without a significant clinical and objective response. The treatment consisted of 40 nivoluumab injections, after which complete remission was achieved.
Keywords: refractory course of, therapy with PD-1 signaling pathway inhibitors

About the Autors

Corresponding author: Mariya Yu. Kichigina, MD, Oncologist, Department of Chemotherapy of Hemoblastosis, Division of Hematology and Bone Marrow Transplantation, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia; e-mail: kitchmar@mail.ru
Address: 24, Kashirskoye Highway, Moscow, 115478 Russian Federation

Бионика Медиа